HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ayako Kaneda Selected Research

Paroxetine (Paxil)

1/2018Effects of personality on the association between paroxetine plasma concentration and response.
5/2016Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder.
9/2015Changes in the Temperament and Character Inventory dimensions after paroxetine treatment in patients with major depressive disorder.
1/2015Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.
8/2014An investigation of temperament and character inventory items for predicting the response to paroxetine treatment in patients with major depressive disorder.
8/2014Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders.
1/2014Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response.
1/2014The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
2/2012The association between sunshine duration and paroxetine response time in patients with major depressive disorder.
12/2011Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ayako Kaneda Research Topics

Disease

12Major Depressive Disorder (Major Depressive Disorders)
01/2018 - 12/2011
3Schizophrenia (Dementia Praecox)
01/2013 - 03/2006
2Alzheimer Disease (Alzheimer's Disease)
01/2014 - 05/2004
1Cognitive Dysfunction
06/2012
1Body Weight (Weight, Body)
03/2006
1Neurobehavioral Manifestations
03/2006

Drug/Important Bio-Agent (IBA)

10Paroxetine (Paxil)FDA LinkGeneric
01/2018 - 12/2011
4Pharmaceutical PreparationsIBA
08/2014 - 03/2006
2Therapeutic UsesIBA
08/2014 - 01/2014
2Antipsychotic Agents (Antipsychotics)IBA
06/2012 - 03/2006
1Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
01/2014
1Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
01/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2014
1Amyloid beta-PeptidesIBA
01/2014
1Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA
01/2013
1Olanzapine (Zyprexa)FDA Link
06/2012
1Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
06/2012
1Risperidone (Risperdal Consta)FDA LinkGeneric
06/2012
1Aripiprazole (Abilify)FDA Link
06/2012
1Antidepressive Agents (Antidepressants)IBA
12/2011
1Donepezil (Aricept)FDA LinkGeneric
05/2004